Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 8,270 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: IGT - Impaired Glucose Tolerance, T2D
Interventions: Oral Glucose Tolerance Test, Hyperglycemic Clamp, Isoglycemic Intravenous Glucose Test, Hyperinsulinemic Euglycemic Clamp and 2H20; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stress-exposed Urban Male Youth
Interventions: Mindfulness-based stress reduction; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematological Malignancy
Interventions: Isatuximab SAR650984, Dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2023
U.S. locations: 16
States / cities: Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more

Conditions: Dravet Syndrome (DS), Children Under 2 Years
Interventions: fenfluramine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Months to 24 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions: eSSET-CINV; Behavioral
Lead sponsor: University of Central Florida; Other
Eligibility: 60 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Multiple Myeloma
Interventions: Vorinostat, Lenalinomide and Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Vestibular Function Tests
Interventions: Computerized Rotational Head Impulse Test ( crHIT)-Vertical; Device
Lead sponsor: Neurolign; Industry
Eligibility: 22 Years to 69 Years
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Neovascular Age Related Macular Degeneration
Interventions: OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic; Device · Drug
Lead sponsor: Retina Macula Institute; Other
Eligibility: 50 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Torrance, California

Conditions: Disabilities Multiple
Interventions: Electonic health record prompts with education, Standard of care; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 3 Years to 89 Years
Enrollment: 120,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease
Interventions: florbetapir F 18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Jenkintown, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Influenza vaccine; Biological
Lead sponsor: Bassett Healthcare; Other
Eligibility: 40 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Peripheral Arterial Disease, Intermittent Claudication, Peripheral Vascular Disease
Interventions: Magnetic Resonance Angiography; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Normal Physiology
Interventions: Pupillometry, Light box exposure; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hearing Loss
Interventions: Phonak Audeo Lumity Receiver in Canal Hearing Aid; Device
Lead sponsor: University of South Florida; Other
Eligibility: 55 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Infection
Interventions: Grapefruit Juice; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder Syndrome
Interventions: Device Morpheus8V; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Corona del Mar, California • Knoxville, Tennessee

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 57
States / cities: Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more

Conditions: Autism, Autism Spectrum Disorder
Interventions: 8 International Units (IU) of Oxytocin, 24IU of Oxytocin, 48IU of Oxytocin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cerebral Palsy
Interventions: Robotic Trunk-Support-Trainer (TruST), Static Trunk Support; Device
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New York, New York

Conditions: ACL Injury
Interventions: Magnetic Resonance Imaging (MRI), ACL reconstruction; Diagnostic Test · Procedure
Lead sponsor: Andrews Research & Education Foundation; Other
Eligibility: 14 Years to 24 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Zolpidem (SL800750); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Breast Cancer
Interventions: Comprehensive Health Enhancement Support System (CHESS.); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vestibular Disorder, Aging
Interventions: Subperceptual Stimulus, Sham Comparator; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Search by objective public record fields.

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

Improving Wellness for Young Men

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

Computerized Rotational Head Impulse Test-Vertical (crHIT-vertical)

Brain-Gut Interactions in Crohn's Disease

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

End Diagnostic Overshadowing

A Study of 18F-AV-45 in Healthy Volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

Non-Contrast Enhanced Peripheral Magnetic Resonance Angiography

Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms

Early Age-Related Hearing Loss Investigation Pilot Study

Gastrointestinal Implications of Voriconazole Exposure

Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Autism Oxytocin Brain Project

Robotic TruST-Postural Intervention for Children With Cerebral Palsy

Andrews Return to Sport ACL Score

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Moderating the Negative Impact of Abnormal Screening Mammograms

Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait